MX2011006433A - Enzastaurina para el tratamiento de cancer. - Google Patents

Enzastaurina para el tratamiento de cancer.

Info

Publication number
MX2011006433A
MX2011006433A MX2011006433A MX2011006433A MX2011006433A MX 2011006433 A MX2011006433 A MX 2011006433A MX 2011006433 A MX2011006433 A MX 2011006433A MX 2011006433 A MX2011006433 A MX 2011006433A MX 2011006433 A MX2011006433 A MX 2011006433A
Authority
MX
Mexico
Prior art keywords
cancer
patient
hdac2
enzastaurin
sample
Prior art date
Application number
MX2011006433A
Other languages
English (en)
Spanish (es)
Inventor
Gopinath Ganji
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MX2011006433A publication Critical patent/MX2011006433A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/15—Depsipeptides; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
MX2011006433A 2008-12-15 2009-12-07 Enzastaurina para el tratamiento de cancer. MX2011006433A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12245108P 2008-12-15 2008-12-15
PCT/US2009/066925 WO2010074936A2 (en) 2008-12-15 2009-12-07 Enzastaurin for the treatment of cancer

Publications (1)

Publication Number Publication Date
MX2011006433A true MX2011006433A (es) 2011-07-19

Family

ID=41785627

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011006433A MX2011006433A (es) 2008-12-15 2009-12-07 Enzastaurina para el tratamiento de cancer.

Country Status (11)

Country Link
US (1) US20110288032A1 (cg-RX-API-DMAC10.html)
EP (1) EP2376081A2 (cg-RX-API-DMAC10.html)
JP (1) JP2012512157A (cg-RX-API-DMAC10.html)
KR (1) KR20110084533A (cg-RX-API-DMAC10.html)
CN (1) CN102245184A (cg-RX-API-DMAC10.html)
AU (1) AU2009330492A1 (cg-RX-API-DMAC10.html)
BR (1) BRPI0922367A2 (cg-RX-API-DMAC10.html)
CA (1) CA2746085A1 (cg-RX-API-DMAC10.html)
EA (1) EA201170821A1 (cg-RX-API-DMAC10.html)
MX (1) MX2011006433A (cg-RX-API-DMAC10.html)
WO (1) WO2010074936A2 (cg-RX-API-DMAC10.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX380504B (es) 2010-06-03 2025-03-12 Pharmacyclics Llc El uso de inhibidores de la tirosina quinasa de bruton (btk).
WO2013112598A1 (en) * 2012-01-24 2013-08-01 Millennium Pharmaceuticals, Inc. Method of treatment of nasopharyngeal caner
WO2013112601A1 (en) * 2012-01-24 2013-08-01 Millennium Pharmaceuticals, Inc. Methods of treatment of cancer
EP2814493A4 (en) * 2012-02-17 2015-07-22 Pharmacyclics Inc COMBINATIONS OF HISTONE DEACETYLASE INHIBITOR AND PAZOPANIB, AND USES THEREOF
HK1206073A1 (en) 2012-07-24 2015-12-31 药品循环有限责任公司 Mutations associated with resistance to inhibitors of bruton's tyrosine kinase (btk)
AU2014290012B2 (en) * 2013-07-19 2020-01-16 Onyx Therapeutics, Inc. Peptide epoxyketone proteasome inhibitors in combination with PIM kinase inhibitors for treatment of cancers
US9885086B2 (en) 2014-03-20 2018-02-06 Pharmacyclics Llc Phospholipase C gamma 2 and resistance associated mutations
WO2017011314A1 (en) * 2015-07-10 2017-01-19 Paharmacyclics Llc Btk and hdac combinations
WO2020223657A1 (en) * 2019-05-02 2020-11-05 Predictive Technology Group, Inc. Somatic cancer driver mutations in endometriosis lesions contribute to secondary cancer risk

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1449529B1 (en) 1993-12-23 2010-01-27 Eli Lilly And Company Protein Kinase C Inhibitors
US20080096923A1 (en) * 2004-07-23 2008-04-24 Aniz Girach Methods For Diagnosing And Treating Diabetic Microvascular Complications
US20090202659A1 (en) * 2005-06-10 2009-08-13 Gimble Jeffrey M Modulation of Peripheral Clocks in Adipose Tissue

Also Published As

Publication number Publication date
AU2009330492A1 (en) 2010-07-01
CN102245184A (zh) 2011-11-16
KR20110084533A (ko) 2011-07-25
US20110288032A1 (en) 2011-11-24
CA2746085A1 (en) 2010-07-01
WO2010074936A2 (en) 2010-07-01
WO2010074936A3 (en) 2010-09-16
EP2376081A2 (en) 2011-10-19
EA201170821A1 (ru) 2011-12-30
JP2012512157A (ja) 2012-05-31
BRPI0922367A2 (pt) 2016-05-24

Similar Documents

Publication Publication Date Title
Pan et al. The chemotherapeutic CX-5461 primarily targets TOP2B and exhibits selective activity in high-risk neuroblastoma
Gooding et al. The lncRNA BORG facilitates the survival and chemoresistance of triple-negative breast cancers
Oh et al. POLQ inhibition elicits an immune response in homologous recombination–deficient pancreatic adenocarcinoma via cGAS/STING signaling
US20110288032A1 (en) Enzastaurin for the treatment of cancer
Du et al. 5-Fluorouracil targets histone acetyltransferases p300/CBP in the treatment of colorectal cancer
Wang et al. LncRNA MALAT1 accelerates non‐small cell lung cancer progression via regulating miR‐185‐5p/MDM4 axis
Agnihotri et al. Alkylpurine–DNA–N-glycosylase confers resistance to temozolomide in xenograft models of glioblastoma multiforme and is associated with poor survival in patients
Lu et al. SIK2 inhibition enhances PARP inhibitor activity synergistically in ovarian and triple-negative breast cancers
Li et al. BCL6 is regulated by the MAPK/ELK1 axis and promotes KRAS-driven lung cancer
CA3063450A1 (en) Companion diagnostics for mitochondrial inhibitors
Hou et al. The NuRD complex-mediated p21 suppression facilitates chemoresistance in BRCA-proficient breast cancer
Zhang et al. Long noncoding RNA HAS2‐AS1 promotes tumor progression in glioblastoma via functioning as a competing endogenous RNA
Liang et al. Tumor promoting long non‐coding RNA CASC15 affects HMGB2 expression by sponging miR‐582‐5p in colorectal cancer
Ciccone et al. Inhibition of poly (ADP-ribose) polymerase induces synthetic lethality in BRIP1 deficient ovarian epithelial cells
WO2020051342A1 (en) Methods for treating metastatic disease using ribosome biogenesis inhibitor cx 5461
US20230416830A1 (en) Methods and compositions for predicting and treating uveal melanoma
US20210060006A1 (en) Compositions and methods for treating glioblastoma by modulating a mgmt enhancer
US20210220471A1 (en) Methods of using pharmacologic inhibitors of type 2 cytokine signaling to treat or prevent pancreatic cancer
KR101999476B1 (ko) Alk 저해제에 내성을 획득한 eml4-alk 양성 비소세포폐암의 치료를 위한 약물 선택의 정보 제공 방법
US20260137678A1 (en) Methods for treating or preventing neuroendocrine tumor formation using xpo1 inhibitors
US20250263799A1 (en) Methods of treating cancer using replication stress modulators
EP4473972A1 (en) Combinations comprising an atr inhibitor with synergistic effect against gliomas
De Los Santos et al. A novel combination of CDK4/6 and PI3K inhibitors exhibits highly synergistic activity and translational potential in Ewing sarcoma
EP4260873A1 (en) Combination drug for treating kidney cancer and therapeutic effect enhancer for tyrosine kinase inhibitor
Kuzmickas Therapeutic Targeting of Chromatin Modifiers in Advanced Prostate Cancer

Legal Events

Date Code Title Description
FA Abandonment or withdrawal